Empagliflozin
6 NDCs across 1 manufacturer|0 Generic,6 Brand
Empagliflozin is used to treat type 2 diabetes mellitus, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Aug 1, 2014, and the first generic was approved Aug 3, 2022. In 2024, Medicare Part D spent $11.4 billion on Empagliflozin across 11.4 million claims for 2.5 million beneficiaries.
Empagliflozin is available as 6 NDCs from 1 manufacturer (0 generic, 6 brand), with NADAC prices from $11.19 to $11.19 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
6
0G / 6B
Manufacturers
1
competing in market
Price Spread
$11.19 – $11.19
per EA
7d Activity
avg +0.0% WoW · of 6 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Sodium-Glucose Cotransporter 2 Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing EMPAGLIFLOZIN
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
JARDIANCE 25 MG TABLET | $11.1897 per EA | +0.04% |
JARDIANCE 25 MG TABLET | $11.1897 per EA | +0.04% |
JARDIANCE 25 MG TABLET | $11.1897 per EA | +0.04% |
JARDIANCE 10 MG TABLET | $11.1893 per EA | +0.01% |
JARDIANCE 10 MG TABLET | $11.1893 per EA | +0.01% |
JARDIANCE 10 MG TABLET | $11.1893 per EA | +0.01% |
Frequently Asked Questions
What is Empagliflozin used to treat?
Empagliflozin is used to treat type 2 diabetes mellitus, per the National Library of Medicine's MED-RT classification.
When did Empagliflozin become available as a generic?
FDA approved the first generic Empagliflozin (ANDA) on Aug 3, 2022.
How much does Medicare spend on Empagliflozin?
In 2024, Medicare Part D spent $11.4 billion on Empagliflozin across 11.4 million claims for 2.5 million beneficiaries.
How many Empagliflozin products are on the market?
The Empagliflozin drug market contains 6 NDCs from 1 manufacturer — 0 generic and 6 brand products.
What is the price range for Empagliflozin?
NADAC reference prices for Empagliflozin range from $11.1893 to $11.1897 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Empagliflozin?
1 manufacturer lists Empagliflozin in NADAC. Ranked by number of NDCs, the largest are Boehringer Ingelheim Pharmaceuticals Inc. (6).
How has the price of Empagliflozin changed recently?
Over the past 7 days, 6 Empagliflozin NDCs rose and 0 fell, with a market-wide average change of +0.0%.